Lynx1 Capital Management LP and Weston Nichols Report Ownership in Cullinan Therapeutics, Inc.

Lynx1 Capital Management LP and Weston Nichols have reported their ownership in Cullinan Therapeutics, Inc. (CGEM) through a Form 3 filing. Lynx1 Master Fund LP holds the securities directly, with Lynx1 Capital Management LP serving as the investment manager. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, is the general partner of the Investment Manager. Both the Investment Manager and Mr. Nichols disclaim beneficial ownership of the securities for purposes of Section 16 of the Securities and Exchange Act of 1934, except to the extent of their pecuniary interest. The filing indicates that Lynx1 Capital Management LP and Weston Nichols each own 7,089,443 shares of common stock in Cullinan Therapeutics, Inc.